Skip to main content

Table 4 Number of events, median survival time, and 6-month, 1-year, and 2-year survival rates, with 95% confidence intervals in the therapy line before a possible inclusion into the SHERBOC trial

From: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

  Progression-free survival Overall survival
SHERBOC no SHERBOC yes SHERBOC no SHERBOC yes
At risk 306 74 306 74
Events 169 18 87 2
Median survival time (months) 11.3 (8.9, 16.1)
6-month survival rate 0.66 (0.61, 0.72) 0.83 (0.74, 0.92) 0.84 (0.80, 0.88) 1.00 (1.00, 1.00)
1-year survival rate 0.48 (0.42, 0.55) 0.76 (0.65, 0.88) 0.72 (0.66, 0.77) 0.96 (0.90, 1.00)
2-year survival rate 0.34 (0.28, 0.41) 0.63 (0.49, 0.82) 0.62 (0.55, 0.69) 0.96 (0.90, 1.00)
\